What the BPC-157 / TB-500 blend is
This product, usually searched as BPC157 TB500 or the BPC-157 TB-500 blend, is a co-lyophilised preparation of two peptides that laboratories very often order together: BPC-157, the 15-residue fragment of a human gastric protein, and TB-500, the N-acetylated seven-residue fragment of thymosin beta-4 that contains its actin-binding motif. The two are dissolved together in the stated amounts, 10 mg of each, freeze-dried together in a single vial. The resulting powder is a physical mixture at a fixed one-to-one ratio by mass, not a conjugate; the peptides are not covalently linked and behave independently once in solution.
BPC-157 has an average molecular weight of approximately 1,419 g/mol and TB-500 approximately 889 g/mol, so 10 mg of each represents different molar quantities, roughly 7 micromoles of BPC-157 and 11 micromoles of TB-500. Neither component carries a lipid, a disulfide or a metal, and the blend is listed in our blends class alongside the other co-lyophilised vials.
The published literature on the compound, with references, is collected in the monograph.
What you receive
Each vial contains the two peptides as a white lyophilised powder, sealed with a flip-off cap over a crimped stopper, in the net quantities stated on the label: 10 mg of BPC-157 and 10 mg of TB-500, 20 mg of peptide in total. There is no carrier, mannitol or other excipient unless the batch certificate says otherwise. The batch number is printed on the label and matches the certificate in our register. The limitation of a blend is its fixed ratio; a design that needs one component varied while the other is held constant should use the single-compound vials.
Reading the certificate for a blend batch
A blend certificate reads slightly differently from a single-compound one. Identity by LC-MS is confirmed for each component in turn: the laboratory looks for the expected mass of about 1,419 Da for BPC-157 and about 889 Da for TB-500, and both must be present. Purity by reversed-phase HPLC shows two well-separated main peaks rather than one, and the reported purity is the combined area of the two main peaks against all peaks. It should be above 98% for a well-made lot. Net content is reported for the vial as a whole; where the laboratory has quantified each peak against a standard, the per-component figures are given too.
The impurities expected are the same as for the individual peptides, chiefly deletion sequences and a small amount of aspartimide-related product from the Asp-Asp pair in BPC-157. Our guide to reading a certificate of analysis includes a blend example, and HPLC and LC-MS explained describes the methods.
Storage and handling
Sealed vials should be kept refrigerated at 2 to 8 °C and protected from light; −20 °C is preferable for storage beyond a few months. Both components are relatively robust short peptides, and the lyophilised blend is stable for well over a year under those conditions. Allow the vial to reach room temperature before opening to avoid condensation. The powder dissolves readily in water or bacteriostatic water to give a clear solution containing both peptides; solutions should be aliquoted and frozen for anything beyond short-term refrigerated use. The storage and stability guide covers solvents, concentrations and freeze-thaw behaviour.